Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor

Overview

RATIONALE: Donepezil and EGb761 may be effective in improving neurocognitive function (such as thinking, attention, concentration, and memory) and may improve quality of life in patients who have undergone radiation therapy to the brain. PURPOSE: This phase II trial is studying how well donepezil or EGb761 works in improving neurocognitive function in patients who have undergone radiation therapy for primary brain tumor or brain metastases.

Full Title of Study: “Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Supportive Care
    • Masking: Double
  • Study Primary Completion Date: May 1, 2005

Detailed Description

OBJECTIVES: Primary – Determine the effect of donepezil or EGb761 on neurocognitive function in patients who underwent radiotherapy for a primary brain tumor or brain metastases at least 6 months before study registration. Secondary – Determine the toxicity of these drugs in these patients. – Determine the quality of life of patients treated with these drugs. – Quantify the extent of radiation-induced white matter disease and temporal lobe atrophy in patients treated with these drugs. OUTLINE: This is an open-label, multicenter study. – Group 1 (closed to accrual 10/09/03): Patients receive oral donepezil once daily for 24 weeks. – Group 2: Patients receive oral EGb761 three times daily for 24 weeks. In both groups (group 1 closed to accrual 10/09/03), treatment continues in the absence of unacceptable toxicity. In both groups (group 1 closed to accrual 10/09/03), quality of life and neurocognitive assessment is performed at baseline and at weeks 6 (group 1 only), 12, 24, and 30. Patients are followed at 6 weeks. PROJECTED ACCRUAL: A total of 70 patients (35 per treatment group) will be accrued for this study within 9.5 months. (Group 1 closed to accrual 10/09/03)

Interventions

  • Dietary Supplement: EGb761
  • Drug: donepezil hydrochloride
  • Procedure: cognitive assessment

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Diagnosis of primary brain tumor or brain metastases, meeting 1 of the following criteria: – No radiographic evidence of disease – Stable disease, defined as no tumor progression within the past 3 months – Previously treated with 1 course of localized or whole brain radiotherapy of at least 3,000 cGy at least 6 months before study registration PATIENT CHARACTERISTICS: Age – 18 and over Performance status – Karnofsky 70-100% Life expectancy – At least 30 weeks Hematopoietic – Not specified Hepatic – Not specified Renal – Not specified Other – Not pregnant or nursing – Negative pregnancy test PRIOR CONCURRENT THERAPY: Biologic therapy – Not specified Chemotherapy – No concurrent chemotherapy Endocrine therapy – Concurrent steroid therapy allowed if on stable or decreasing dose Radiotherapy – See Disease Characteristics – No concurrent cranial radiotherapy Surgery – No concurrent surgery Other – More than 3 months since prior donepezil or EGb761 – No concurrent donepezil (group 2 only) – No concurrent EGb761 (group 1 only) (closed to accrual 10/09/03) – No concurrent anticoagulants (e.g., aspirin, dipyridamole, heparin, warfarin, or enoxaparin) (group 2 only) – No concurrent monoamine oxidase inhibitors (e.g., phenelzine or tranylcypromine) – No other concurrent therapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Wake Forest University Health Sciences
  • Collaborator
    • National Cancer Institute (NCI)
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Edward G. Shaw, MD, Study Chair, Wake Forest University Health Sciences

Citations Reporting on Results

Shaw EG, Rosdhal R, D'Agostino RB Jr, Lovato J, Naughton MJ, Robbins ME, Rapp SR. Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol. 2006 Mar 20;24(9):1415-20. doi: 10.1200/JCO.2005.03.3001.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.